Mark Therapeutics
Organisation
People
President and cso, 28 Aug 2026, reporter.nih.gov
Grants and prizes
National Institute of Neurological Disorders and Stroke
R44, Gene Therapy for Idiopathic Parkinson's Disease: In Vivo Validation, R44NS134446, US$862.5k, 2024–2029, 28 Aug 2026, reporter.nih.gov
National Institute of Neurological Disorders and Stroke
R43, Gene Therapy for Idiopathic Parkinson's Disease, R43NS134446, US$192.2k, 2024–2026, 25 Jul 2025, reporter.nih.gov